SCHEMBL12092675

SCHEMBL12092675

CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CCC(=O)NCC[C@@H](C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 9/20 0.55
▸ MC1R Q01726 5/20 0.55
▸ TUBB4A P04350 2/20 0.50
▸ TUBB P07437 2/20 0.50
▸ TUBA3C P0DPH7 2/20 0.50
▸ TUBA1B P68363 2/20 0.50
▸ TUBA4A P68366 2/20 0.50
▸ TUBB4B P68371 2/20 0.50
▸ TUBB3 Q13509 2/20 0.50
▸ TUBB2A Q13885 2/20 0.50
▸ TUBB8 Q3ZCM7 2/20 0.50
▸ TUBA3E Q6PEY2 2/20 0.50
▸ TUBA1A Q71U36 2/20 0.50
▸ TUBA1C Q9BQE3 2/20 0.50
▸ TUBB6 Q9BUF5 2/20 0.50
▸ TUBB2B Q9BVA1 2/20 0.50
▸ TUBB1 Q9H4B7 2/20 0.50
▸ TSLP Q969D9 1/20 0.49
▸ FURIN P09958 1/20 0.48
▸ ACE2 Q9BYF1 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206326 0.96 MC4R (0.59) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL20206360 0.95 MC4R (0.59) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL20206236 0.94 MC4R (0.52) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL12092693 0.94 MC4R (0.52) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL21392393 0.94 MC4R (0.52) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL21392395 0.94 MC4R (0.52) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL12092634 0.93 MC4R (0.55) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL20206245 0.93 MC4R (0.55) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL21392451 0.91 MC4R (0.56) MC4RMC1RTUBB4ATUBBTUBA3C
SCHEMBL22606151 0.91 MC4R (0.56) MC4RMC1RTUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy PALATIN TECHNOLOGIES, INC. (US) 2022-03-29 — — US disclosed
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy PALATIN TECHNOLOGIES INC (US) 2020-10-29 — — US disclosed
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine PALATIN TECHNOLOGIES, INC. (US) 2020-07-14 — — US disclosed
WO-2019183472-A1 MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC DELIVERY PALATIN TECHNOLOGIES, INC. (US) 2019-09-26 — — WO disclosed
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides PALATIN TECHNOLOGIES, INC. (US) 2018-07-10 — — US disclosed
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine PALATIN TECHNOLOGIES INC (US) 2018-05-31 — — US disclosed
US-20170008931-A1 Melanocortin-1 Receptor-Specific Cyclic Hexapeptides PALATIN TECHNOLOGIES INC (US) 2017-01-12 — — US disclosed
US-9447148-B2 Melanocortin-1 receptor-specific cyclic peptides PALATIN TECHNOLOGIES, INC. (US) 2016-09-20 — — US disclosed
US-20150038434-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides PALATIN TECHNOLOGIES INC (US) 2015-02-05 — — US disclosed
US-8877890-B2 Melanocortin-1 receptor-specific cyclic peptides PALATIN TECHNOLOGIES, INC. (US) 2014-11-04 — — US disclosed
US-20130296256-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides PALATIN TECHNOLOGIES, INC. (US) 2013-11-07 — — US disclosed
US-8492517-B2 Melanocortin-1 receptor-specific cyclic peptides PALATIN TECHNOLOGIES, INC. (US) 2013-07-23 — — US disclosed
US-20120225828-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides PALATIN TECHNOLOGIES, INC. (US) 2012-09-06 — — US disclosed
WO-2011063366-A1 MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2011-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine MC1R, MC3R, MC4R MC4R 3/4885MC1R 1/4885TUBB4A 3433/4885
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy MC3R, MC1R, MC2R MC4R 6/4885MC1R 2/4885TUBB4A 4234/4885
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides MC1R, MC3R, MC5R MC4R 4/4885MC1R 1/4885TUBB4A 4844/4885
US-20120225828-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides MC1R, MC3R, MC5R MC4R 4/4885MC1R 1/4885TUBB4A 4704/4885
US-20150038434-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides MC1R, MC3R, MC5R MC4R 4/4885MC1R 1/4885TUBB4A 4704/4885
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy MC3R, MC1R, MC2R MC4R 6/4885MC1R 2/4885TUBB4A 4234/4885
US-20170008931-A1 Melanocortin-1 Receptor-Specific Cyclic Hexapeptides MC1R, MC3R, MC5R MC4R 4/4885MC1R 1/4885TUBB4A 4844/4885
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine MC1R, MC3R, MC4R MC4R 3/4885MC1R 1/4885TUBB4A 3433/4885
US-20130296256-A1 Melanocortin-1 Receptor-Specific Cyclic Peptides MC1R, MC3R, MC5R MC4R 4/4885MC1R 1/4885TUBB4A 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback